- For investors considering whether Artivion at around US$35 per share still offers value or whether the recent run has already priced in the story, this article breaks down what the current market price might be implying.
- The stock has pulled back over the last week and month, with declines of 1.2% and 8.3%, respectively, while still sitting on a 43.6% return over 1 year and 176.1% over 3 years.
- Recent coverage has focused on Artivion's position in the medical equipment space and investor interest around its long term growth profile. This helps explain why the share price has been sensitive to changing expectations. At the same time, discussions around healthcare demand and procedure volumes have kept the stock on the radar of investors reassessing risk and reward.
- Artivion currently has a valuation score of 1 out of 6. The next sections will walk through what different valuation methods suggest about that score and introduce another way to think about value, which is discussed at the end of the article.
Artivion scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Artivion Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. It is essentially asking what those future dollars are worth in today's terms.
For Artivion, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is reported at $6.34 million. Simply Wall St then projects free cash flow over the coming years, using analyst estimates where available and extending those projections out to 10 years. By 2035, the model uses an extrapolated free cash flow figure of $53.16 million, with interim years stepping up from 2026 through 2034 based on the provided growth assumptions.
After discounting all those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $15.95 per share. Compared with a market price around $35, this implies Artivion is assessed as 121.3% overvalued under this approach.
Result: OVERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Artivion may be overvalued by 121.3%. Discover 62 high quality undervalued stocks or create your own screener to find better value opportunities.
Approach 2: Artivion Price vs Sales
For profitable companies where revenue is a key driver of scale, the Price to Sales, or P/S, ratio can be a useful way to gauge what investors are paying for each dollar of sales. It is especially common in sectors like medical equipment, where earnings can be influenced by investment cycles and accounting items, while revenue can provide a cleaner read on business traction.
Growth expectations and risk usually shape what investors see as a normal P/S multiple, with higher expected growth and lower perceived risk often supporting a higher ratio. Artivion currently trades on a P/S of 3.83x, compared with the Medical Equipment industry average of 2.69x and a peer group average of 3.30x. Simply Wall St also provides a proprietary “Fair Ratio” of 2.42x, which reflects the P/S multiple implied by factors such as earnings growth, industry, profit margin, market cap and risk profile.
This Fair Ratio can be more tailored than simple comparisons with peers or the sector, because it adjusts for Artivion’s specific characteristics rather than applying a broad brush average. With the current 3.83x P/S sitting above the 2.42x Fair Ratio, the stock screens as more expensive than what this framework suggests.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Artivion Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Artivion into a clear story that links what the business is doing to a forecast for revenue, earnings and margins, and then to a fair value you can compare with the current price. This all sits inside an easy tool on the Community page that updates automatically when new news or earnings arrive. One investor might build a higher fair value Narrative around strong adoption of products like AMDS and NEXUS and a P/E near the higher analyst target of US$50. Another might focus on regulatory, leverage and pricing risks and land closer to the lower US$38.80 target. Both can see in one place how their assumptions flow through to a number and use that to decide whether the current price looks high or low against their own story.
Do you think there's more to the story for Artivion? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com